Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma
Five Prime Therapeutics’ investigational drug bemarituzumab showed promising efficacy in the late-line treatment of gastroesophageal junction adenocarcinoma.
BeiGene bags option on Leap cancer drug, requests PD-1 combination trial
BeiGene and Leap Therapeutics have teamed up to study a combination of an anti-DKK1 antibody with the anti-PD-1 antibody tislelizumab in patients... Read More
BeiGene bags option on Leap cancer drug, requests PD-1 combination trial
BeiGene and Leap Therapeutics have teamed up to study a combination of an anti-DKK1 antibody with the anti-PD-1 antibody tislelizumab in patients... Read More
Predictors of Response to Immune Checkpoint Inhibitors in Patients With Advanced Esophagogastric Cancer
In a recent trial of checkpoint inhibitors in gastric or esophageal cancer, patients who reported immune-related side effects also showed longer survival... Read More
Oncologie Pairs PS Inhibitor Bavituximab with Merck’s Keytruda for Gastric Cancer
A new clinical trial pairs Oncologie’s bavituximab with Merck’s Keytruda in advanced stomach or gastroesophageal cancer.
Perioperative FOLFIRINOX for Gastroesophageal Adenocarcinoma
In a trial, the chemotherapy regimen FOLFIRINOX produced response rates on par with FLOT and may be easier to tolerate, says Dan... Read More
Perioperative Fluorouracil + Leucovorin, Oxaliplatin, and Docetaxel vs Fluorouracil or Capecitabine + Cisplatin and Epirubicin for Locally Advanced, Resectable Gastric or GE Junction Adenocarcinoma
A phase II/III trial investigated a chemotherapy triplet, FLOT (docetaxel, oxaliplatin, 5-FU/LV), as perioperative therapy in resectable gastroesophageal cancers compared with ECF/ECX,... Read More
FDA Grants Priority Review to TAS-102 for Gastric/GEJ Cancer
Shared in OncLive, the FDA has granted priority review to a supplemental new drug application for TAS-102 (trifluridine/tipiracil; Lonsurf) for use in... Read More
Taiho Oncology and Servier Announce Positive Results from LONSURF® (trifluridine/tipiracil) Study Presented at ESMO 2018 Congress and Published in The Lancet Oncology
Lonsurf receives FDA priority review for metastatic gastric cancer, with a new study presented at ESMO 2018 Congress and published in The... Read More